Explore immunotherapy resistance in melanoma with Dr. Camelia Quek through advanced spatial multiomics and single-cell analysis insights.
Heterogeneous resistance to immunotherapy remains a significant challenge in cancer treatment, driven by intrinsic genetic traits of the tumor and extrinsic factors within the tumor microenvironment (TME). Join us for an insightful webinar, where Dr. Camelia Quek presents on the innovative use of longitudinal multimodal single-cell analysis and spatial inference to uncover the complexities of the tumor microenvironment (TME) of advanced melanoma patients with innate resistance, acquired resistance, or response to immunotherapy.
Key Topics Include:
- Integration of single-cell sequencing and spatial datasets to understand the biological insights of innate and acquired resistance to immunotherapy
- The identification of immune-striving phenotypes and the emergence of specific melanoma subclones post-therapy
- The role of B cell signatures and lymphoid aggregates in therapeutic outcomes
- Immune hotspot in melanoma patients treated with neoadjuvant immunotherapy
Attendees will gain a deeper understanding of how these discoveries can inform future therapeutic strategies and improve patient outcomes.
Click to watch the webinar recording. To view the presentation full screen simply click the square icon located in the bottom-right corner of the video-viewer.
Presenters
CINSW Research Fellow and Honorary Senior Research Fellow
Melanoma Institute Australia and University of Sydney
Dr. Camelia Quek is a CINSW Research Fellow at Melanoma Institute Australia and is appointed as an Honorary Senior Research Fellow at the University of Sydney. Dr Quek has training in both molecular biology and bioinformatics, where she originally did a first degree in molecular biology at the University of New South Wales before moving on to do a PhD in Neuroscience and Computational Biology at the University of Melbourne. Dr Quek has extensive experience in integrating cutting-edge techniques and sophisticated computation methods to solve clinically important questions that associate with strong clinical implementations. She is currently leading the Translational Bioinformatics and Data Analytics Program for cancer therapy studies that resulted in several key publications (e.g. Cancer Cell and Nature Publishing Group Journals) in identifying molecular determinants of response and resistance in patients with advanced melanoma treated with targeted and immune-based therapies. In 2017, she was part of the Melanoma Institute Australia research team that won the CINSW Premier’s Awards for Outstanding Cancer Research. In 2022, she was awarded the prestigious CINSW Wildfire Highly Cited Publication Award for her co-first author paper published in Cancer Cell. Her current research interests are: (1) Biomarkers of response and resistance to cancer therapies, (2) Single-cell multi-omics to understand treatment and progression, and (3) Spatial imaging to dissect key cellular interactions and novel drug targets.
Production Partner
Akoya Biosciences
As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode™ Panels and PhenoCycler® Fusion, PhenoImager® Fusion, and PhenoImager HT Instruments.
Additional Content From Akoya Biosciences
Spatial Biology and the Gastrointestinal Tract: Unveiling Cellular Landscapes and Disease Mechanisms
Discover how spatial biology is reshaping our understanding of the gastrointestinal tract, from cellular diversity to disease mechanisms and treatment insights.
Reprogramming the Brain Tumor Microenvironment to Enhance Anti-Tumor Immunity
Join us to learn how recent discoveries about the brain tumor microenvironment can drive new therapeutic strategies to overcome tumor immunosuppression.
A Ready-to-Analyze High-Plex Spatial Signature Development Workflow for Cancer Immunotherapy
In this webinar, Aditya Pratapa and Lorcan Sherry present a new workflow for analyzing multiplex immunoflurescence images.
Additional Content From Scientist.com
How to Avoid Expensive Redesign Cycles in Antibody Discovery
Learn how integrated antibody discovery and engineering strategies can accelerate the path from hit to optimized lead in less than 12 months while minimizing costly redesign cycles.
Beyond Exposure: Integrating PK/PD for Translational Predictive Power
Learn to integrate PK/PD modeling and strategic biomarkers to bridge the translational gap. Improve clinical predictability for NCEs, ADCs, and large molecules in this technical webinar.
Advancing the Manufacture of Mesenchymal Stromal Cells and Derived Extracellular Vesicles in Stirred-Tank Bioreactors Through Enhanced Bioprocess Control
Learn how to scale the production of MSCs and extracellular vesicles using bioreactor control and real-time monitoring for more consistent therapies.
Related Content
Advancing ADC Development: Leveraging AI and Translational Preclinical Models to Improve Clinical Predictability
Join our webinar to discover how to de-risk ADC development through the integration of AI-driven analytics, mouse clinical trials and specialized translational models.
From Biopsy to Better Decisions: Patient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer
Learn how patient-derived organoids predict treatment response in metastatic colorectal cancer and explore findings from the OPTIC study on drug sensitivity and clinical outcomes.
De-Risking Immunotherapy Targets with Next-Gen HLA Discovery Platforms
In this webinar, Rico Buchli, PhD, shares how next-generation soluble HLA peptide discovery platforms can strengthen early immunotherapy R&D - from target identification and confirmation to receptor/drug validation and translational decision-making.